| Cas No.: | 1110766-97-6 |
| Chemical Name: | Lusutrombopag |
| Synonyms: | Lusutrombopag;S-888711;(2E)-3-[2,6-Dichloro-4-[[[4-[3-[(1S)-1-(hexyloxy)ethyl]-2-methoxyphenyl]-2-thiazolyl]amino]carbonyl]phenyl]-2-methyl-2-propenoic acid;S 888711;mulpleta;6LL5JFU42F;(S,E)-3-(2,6-Dichloro-4-((4-(3-(1-(hexyloxy)ethyl)-2-methoxyphenyl)thiazol-2-yl)carbamoyl)phenyl)-2-methylacrylic acid;2-Propenoic acid, 3-[2,6-dichloro-4-[[[4-[3-[(1S)-1-(hexyloxy)ethyl]-2-methoxyphenyl]-2-thiazolyl]amino]carbonyl]phenyl]-2-methyl-, (2E)-;Lusutrombopag [USAN:INN];Mulpleta (TN);2-Propenoic acid, 3-(2,6-dichloro-4-(((4-(3-((1S)-1-(hexyloxy)ethyl)-2-methoxyphenyl)-2-thiazolyl)amino)carbonyl)phenyl)-2-methyl-, |
| SMILES: | ClC1C([H])=C(C([H])=C(C=1/C(/[H])=C(/C(=O)O[H])\C([H])([H])[H])Cl)C(N([H])C1=NC(=C([H])S1)C1C([H])=C([H])C([H])=C(C=1OC([H])([H])[H])[C@]([H])(C([H])([H])[H])OC([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O |
| Formula: | C29H32Cl2N2O5S |
| M.Wt: | 591.5458 |
| Purity: | >98% |
| Sotrage: | 4°C for 1 year, -20°C for more than 2 years |
| Description: | Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease. |
| In Vitro: | Lusutrombopag acts selectively on the human TPO receptor and activates signal transduction pathways that promote the proliferation and differentiation of bone marrow cells into megakaryocytes, thereby increasing platelet levels[1]. |
| References: | [1]. Kim ES, et al. Lusutrombopag: First Global Approval. Drugs. 2016 Jan;76(1):155-8. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|